Evidence map›Paper›PMID 27659448›Full record

ArticleJapanese journal of radiology2016

Hypofractionated stereotactic radiotherapy (HFSRT) for who grade I anterior clinoid meningiomas (ACM).

Selcuk Demiral, Ferrat Dincoglan, Omer Sager, Hakan Gamsiz, Bora Uysal, Esin Gundem, Yelda Elcim, Bahar Dirican, Murat Beyzadeoglu

Abstract read
PubMed Publisher
In one paragraph

Article in Japanese journal of radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Selcuk DemiralDepartment of Radiation Oncology, Gulhane Medical School, Ankara, Turkey. sdemiral@gata.edu.tr.
Ferrat DincoglanDepartment of Radiation Oncology, Gulhane Medical School, Ankara, Turkey.
Omer SagerDepartment of Radiation Oncology, Gulhane Medical School, Ankara, Turkey.
Hakan GamsizDepartment of Radiation Oncology, Gulhane Medical School, Ankara, Turkey.
Bora UysalDepartment of Radiation Oncology, Gulhane Medical School, Ankara, Turkey.
Esin GundemDepartment of Radiation Oncology, Gulhane Medical School, Ankara, Turkey.
Yelda ElcimDepartment of Radiation Oncology, Gulhane Medical School, Ankara, Turkey.
Bahar DiricanDepartment of Radiation Oncology, Gulhane Medical School, Ankara, Turkey.
Murat BeyzadeogluDepartment of Radiation Oncology, Gulhane Medical School, Ankara, Turkey.
Gülhane Askerî Tıp Akademisi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWhile microsurgical resection plays a central role in the management of ACMs, extensive surgery may be associated with substantial morbidity particularly for tumors in intimate association with critical structures. In this study, we evaluated the use of HFSRT in the management of ACM. MATERIALS AND

methodsA total of 22 patients with ACM were treated using HFSRT. Frameless image guided volumetric modulated arc therapy (VMAT) was performed with a 6 MV linear accelerator (LINAC). The total dose was 25 Gy delivered in five fractions over five consecutive treatment days. Local control (LC) and progression free survival (PFS) rates were calculated using the Kaplan-Meier method. Common Terminology Criteria for Adverse Events, version 4.0 was used in toxicity grading.

resultsOut of the total 22 patients, outcomes of 19 patients with at least 36 months of periodic follow-up were assessed. Median patient age was 40 years old (range 24-77 years old). Median follow-up time was 53 months (range 36-63 months). LC and PFS rates were 100 and 89.4 % at 1 and 3 years, respectively. Only two patients (10.5 %) experienced clinical deterioration during the follow-up period.

conclusionLINAC-based HFSRT offers high rates of LC and PFS for patients with ACMs.

Indexed as

AdultAgedBrain NeoplasmsDisease-Free SurvivalDose Fractionation, RadiationFemaleHumansMaleMeningiomaMiddle AgedNeoplasm GradingParticle AcceleratorsRadiotherapy, Intensity-ModulatedTreatment OutcomeAnterior clinoid meningiomas (ACM)Hypofractionated stereotactic radiotherapy (HFSRT)Linear accelerator (LINAC)

Identifiers

PMID27659448
OpenAlexW2418354681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.